Medication Guide App

Invega

Active Substance: paliperidone
Common Name: paliperidone
ATC Code: N05AX13
Marketing Authorisation Holder: Janssen-Cilag International NV
Active Substance: paliperidone
Status: Authorised
Authorisation Date: 2007-06-25
Therapeutic Area: Psychotic Disorders Schizophrenia
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.

Invega is indicated for the treatment of schizophrenia.

Invega is indicated for the treatment of psychotic or manic symptoms of schizoaffective disorder. Effect on depressive symptoms has not been demonstrated.

What is Invega?

Invega is a medicine that contains the active substance paliperidone. It is available as prolonged-release tablets (1.5, 3, 6, 9 and 12 mg). ‘Prolonged release’ means that paliperidone is released slowly from the tablet over a few hours.

What is Invega used for?

Invega is used in adults and adolescents from 15 years of age to treat schizophrenia, a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).

Invega is also used to treat adults with schizoaffective disorder. This is a condition in which the patient has episodes of elevated or depressed mood in addition to symptoms of schizophrenia. Invega is not effective in treating the depressive symptoms of schizoaffective disorder.

The medicine can only be obtained with a prescription.

How is Invega used?

The recommended starting dose of Invega in adults is 6 mg once a day, taken in the morning; adolescents should start at a dose of 3 mg daily. The tablet should be swallowed whole with a drink. Patients should take Invega either with or without food, but should not switch between taking it with food on one day and without food on another. After assessment of the symptoms, the dose of Invega can be adjusted to between 3 and 12 mg once a day in adults with schizophrenia and to between 6 and 12 mg once a day in patients with schizoaffective disorder. In adolescents with schizophrenia the maximum daily dose depends on the patient’s body weight and should not be more than 6 mg in those who weigh less than 51 kg. Patients with mild or moderate kidney problems, including some elderly patients, should also start with a lower dose of Invega, but the medicine is not recommended for patients with severe kidney problems. For more information on the use of Invega, including the adjustment of doses, see the summary of product characteristics (also part of the EPAR).

How does Invega work?

The active substance in Invega, paliperidone, is an antipsychotic medicine. It is known as an ‘atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Paliperidone is an active breakdown product (metabolite) of risperidone, another atypical antipsychotic medicine that has been used in the treatment of schizophrenia since the 1990s. In the brain, paliperidone attaches to several different receptors on the surface of nerve cells. This disrupts signals transmitted between brain cells by ‘neurotransmitters’, chemicals that allow nerve cells to communicate with each other. Paliperidone acts mainly by blocking the receptors for the neurotransmitters dopamine and 5‑hydroxytryptamine (also called serotonin), which are involved in schizophrenia. By blocking these receptors, paliperidone helps to normalise the activity of the brain and reduce symptoms.

How has Invega been studied?

For schizophrenia, Invega has been studied in three main short-term studies involving 1,692 adults, and one short term study involving 200 adolescents aged 12 to 17 years. In all three adult studies, doses of Invega between 3 and 15 mg a day were compared with placebo (a dummy treatment) and with olanzapine (another antipsychotic medicine). In the adolescent study, doses of Invega between 1.5 and 12 mg a day were compared with placebo.The main measure of effectiveness was the change in the patients’ symptoms using a standard scale for schizophrenia after six weeks. An additional study in adults with schizophrenia looked at the long-term effects of Invega in preventing new symptoms for up to 35 weeks in 207 patients who had initially been treated over a 14-week period, and another study involving 228 adolescents looked at the longer-term effects of treatment with Invega over 8 and 26 weeks compared with aripiprazole (another antipsychotic medicine). A supportive study provided information on the use of Invega in adolescents over up to 2 years.

Two main studies were carried out in adults with schizoaffective disorder. A total of 614 patients were given either Invega or placebo. The main measure of effectiveness was the same as in the main schizophrenia studies: change in the patients’ symptoms after six weeks on a standard scale.

What benefit has Invega shown during the studies?

Invega was more effective than placebo and as effective as olanzapine in reducing the symptoms of schizophrenia in adults. In the first short-term study, patients taking placebo had an average fall in their symptom score of 4.1 points, compared with an average fall of between 17.9 and 23.3 points in those taking Invega and of 19.9 in those taking olanzapine. Similar results were seen in the other two short-term studies. Across all three studies, higher doses of Invega were more effective than lower doses in reducing symptoms. Comparable results were seen at doses above 3 mg in adolescents, although too few patients aged below 15 years were studied to clearly establish an effect in this younger age group.

Invega was also more effective than placebo in preventing the occurrence of new symptoms of schizophrenia in the long-term study in adults, and the overall results of studies were also considered to support longer-term use in adolescents from 15 years of age.

In the studies in adults with schizoaffective disorder, Invega was more effective than placebo. In the first study, patients who were given Invega had a fall in their symptom score of between 27.4 and 30.6 compared with 21.7 in patients who were given placebo. In the second study, the fall in symptom score was 20.0 in the Invega group and 10.8 in the placebo group.

What is the risk associated with Invega?

The most frequently reported side effects in studies with Invega are headache, insomnia (difficulty sleeping), sleepiness, parkinsonism (neurological symptoms including tremor and impaired muscular control), akathisia (restlessness), tachycardia (increased heart rate), dystonia (involuntary muscle contractions), tremor (shaking), upper respiratory tract infection (colds), anxiety, dizziness, increased weight, nausea, agitation, constipation, vomiting, fatigue (tiredness), depression, dyspepsia (heartburn), diarrhoea, dry mouth, toothache, muscle and bone pain, asthenia (weakness), high blood pressure, back pain, prolonged electrocardiogram QT (an alteration of the electrical activity of the heart) and cough. Side effects in adolescents are similar to those in adults, although some side effects may occur more frequently. For the full list of all side effects reported with Invega, see the package leaflet.

Invega should not be taken by people who may be hypersensitive (allergic) to paliperidone or any of the other ingredients, or to risperidone.

Why has Invega been approved?

The CHMP decided that Invega’s benefits are greater than its risks in adults and recommended that it be given marketing authorisation. The CHMP noted that, although Invega is beneficial to adults with schizoaffective disorder, the medicine has not been shown to be effective in treating depressive episodes in these patients. The Committee also considered that the benefits of Invega had been shown to be greater than its risks in the treatment of schizophrenia in adolescents from 15 years of age.

What measures are being taken to ensure the safe and effective use of Invega?

A risk management plan has been developed to ensure that Invega is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Invega, including the appropriate precautions to be followed by healthcare professionals and patients.

Other information about Invega

The European Commission granted a marketing authorisation valid throughout the European Union for Invega on 25 June 2007.

For more information about treatment with Invega, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)